Enfusion (ENFN) Stock Price

Enfusion Price

NYSE·CLOSED
10.76
​
Market closed

Revenue has compounded at 28.2% per year over the past 5 years to 201.61 M USD. Earnings per share have declined at 27.9% per year over the last 5 years. Enfusion's net margin stands at 1.4%, down from 5.2% several years earlier. Analysts set a median price target of 11.48 USD, implying 6.6% above the current price. Of 11 analysts, 0 rate the stock a buy — an overall Hold consensus.

Enfusion stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Enfusion business model & stock analysis

Enfusion Inc. generates revenue through cloud-native multi-tenant software solutions tailored for alternative and institutional investment managers. Its core products include the Portfolio Management System (PMS), Order and Execution Management System (OEMS), Accounting/General Ledger System, and Enfusion Analytics System, which collectively enable real-time investment decision-making. The company serves investment managers who require integrated systems for the full investment lifecycle, with PMS constructing and rebalancing portfolios while generating a real-time investment book of record, and OEMS facilitating electronic trade order communication for portfolio managers, traders, compliance teams, and analysts. The company's solution integrates technology-powered managed services to drive insights and control over investment operations. Enfusion's end-to-end functionality supports the entire investment process, from portfolio construction to trade execution, with PMS and OEMS operating in tandem to provide a seamless workflow. Investment managers across alternative and institutional segments purchase these integrated systems to enhance operational efficiency and decision-making capabilities. Enfusion's software is designed to serve the full investment lifecycle, with its systems integrated to provide a unified platform for portfolio management, order execution, accounting, and analytics. The company's revenue model is based on delivering these comprehensive solutions to investment managers who rely on real-time data and integrated workflows to manage their operations effectively.

Frequently asked questions about Enfusion

Analysts currently set an average price target of 11.15 USD for the Enfusion stock (median: 11.48 USD), implying +3.6 % versus the latest price. The consensus is based on 11 analyst ratings.

11 analysts currently rate the Enfusion stock: 0 recommend buying, 8 holding and 3 selling. For 2026, analysts expect Enfusion to generate revenue of 278.87 M USD and earnings per share of 0.35 USD.

Converted at the current exchange rate, the Enfusion share trades at 9.58 EUR (10.76 USD).

The Enfusion share (ENFN) is listed on 1 stock exchanges, including: NYSE (ENFN).

The expected revenue of Enfusion is 278.87 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Enfusion is 45.23 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Enfusion is currently 30.82. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Enfusion stock.

The price-to-sales ratio (P/S) of Enfusion is currently 5.00. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Enfusion stock.

The Eulerpool Quality Score for Enfusion is 5/10.

The ISIN of Enfusion is US2928121043. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Enfusion is ENFN. The ticker symbol is used to trade Enfusion shares on the stock exchange.

Fair ValueTerminal
10.33 USD
Over-/UndervaluationTerminal
Fairly valued
Industry
Software
Number of shares
Employees
Revenue per Employee
176,387.58 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website enfusion.com
Currency
USD
Initial public offering
Oct 21, 2021
ISIN
US2928121043
Cusip
292812104
Market capitalization
1.40 B USDSmall Cap
52-Week Range
PEG
25.15
P/E ratio
P/Ee 2025
47.17
P/Ee 2026
30.89
P/Ee 2027
27.55
P/S
P/Se
5.87
EV/EBIT
218.15
P/B Ratio
19.08
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
3.86 %
Last updated Nov 6, 2026, 7:33 PM

Enfusion Peer Group

Enfusion Ticker

NEW YORK · ENFN

Enfusion FIGI

ENFN:US · BBG012MBFQD7ENFN:UA · BBG012MBFQF5ENFN:UC · BBG012MBFQG4ENFN:UN · BBG012MBFQJ1ENFN:UP · BBG012MBFQK9ENFN:UB · BBG012MBFQM7ENFN:UT · BBG012MBFQN6ENFN:UM · BBG012MBFQP4ENFN:UX · BBG012MBFQQ3ENFN:UD · BBG012MBFQW6ENFN:UF · BBG012MBFQZ3ENFN:VY · BBG012MBFR09

All fundamentals and in-depth analysis of Enfusion

Our stock analysis for Enfusion stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Enfusion. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.